PLX Share Price Performance
US$2.27
-0.28 (-10.98%)
79.4% undervalued intrinsic discount
US$11.00
Fair Value
Price US$2.27
AnalystConsensusTarget US$11.00
Zwfis US$4.23
Fair ValueUS$11.00
Share Pricen/a
Protalix BioTherapeutics, Inc. Stock Price
- 2 Narratives written by author
- 1 Comments on narratives written by author
- 82 Fair Values set on narratives written by author
PLX Community Narratives
AN
Fair Value US$11 79.4% undervalued intrinsic discount
EMA Reviews And Rare Disease Trends Will Open Global Markets
3users have liked this narrative
0users have commented on this narrative
29users have followed this narrative
ZW
Fair Value US$4.23 46.3% undervalued intrinsic discount
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%.Read more
326
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
EMA Reviews And Rare Disease Trends Will Open Global Markets
Key Takeaways Commercialization and regulatory expansion of Elfabrio, along with pipeline growth, position Protalix for recurring revenue growth and improved patient retention. Platform scalability and partner contracts enhance profitability and offer substantial upside through royalty and milestone payment opportunities.Read more
514
users have viewed this narrative3users have liked this narrative
0users have commented on this narrative
29users have followed this narrative
AN
US$11
79.4% undervalued intrinsic discount
Fair Value
Profit Margin
11.5%
Future PE
126.13x
Price in 2029
US$13.45
Trending Discussion
Recently Updated Narratives
ZW
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
Fair Value: US$4.23 46.3% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Fair Value: US$11 79.4% undervalued intrinsic discount
29 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Protalix BioTherapeutics, Inc. Key Details
About PLX
- Founded
- n/a
- Employees
- 226
- CEO
- WebsiteView website
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
